IRIS
PASSALACQUA, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 59.031
AS - Asia 1.410
SA - Sud America 287
NA - Nord America 176
AF - Africa 39
Continente sconosciuto - Info sul continente non disponibili 2
Totale 60.945
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 58.968
SG - Singapore 687
CN - Cina 315
VN - Vietnam 230
BR - Brasile 176
US - Stati Uniti d'America 114
HK - Hong Kong 57
AR - Argentina 51
MX - Messico 47
IQ - Iraq 23
ID - Indonesia 22
BD - Bangladesh 20
EC - Ecuador 15
VE - Venezuela 13
EG - Egitto 12
CO - Colombia 11
RU - Federazione Russa 11
IN - India 9
JO - Giordania 7
PK - Pakistan 7
CL - Cile 6
GB - Regno Unito 6
PT - Portogallo 6
AT - Austria 5
MA - Marocco 5
PE - Perù 5
TR - Turchia 5
UA - Ucraina 5
UY - Uruguay 5
ZA - Sudafrica 5
DO - Repubblica Dominicana 4
FI - Finlandia 4
JP - Giappone 4
RO - Romania 4
AZ - Azerbaigian 3
BG - Bulgaria 3
CA - Canada 3
DZ - Algeria 3
KE - Kenya 3
KG - Kirghizistan 3
NL - Olanda 3
PY - Paraguay 3
BF - Burkina Faso 2
BO - Bolivia 2
BY - Bielorussia 2
CY - Cipro 2
DE - Germania 2
HU - Ungheria 2
KZ - Kazakistan 2
MY - Malesia 2
NE - Niger 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
CG - Congo 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
ET - Etiopia 1
FR - Francia 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
KR - Corea 1
LB - Libano 1
LT - Lituania 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
MW - Malawi 1
NA - Namibia 1
NG - Nigeria 1
NI - Nicaragua 1
NP - Nepal 1
PL - Polonia 1
PR - Porto Rico 1
SE - Svezia 1
SI - Slovenia 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZM - Zambia 1
Totale 60.945
Salva come PNG Salva come JPEG
Città #
Genova 41.035
Genoa 10.350
Rapallo 4.496
Vado Ligure 2.986
Singapore 447
Ho Chi Minh City 86
Bordighera 71
Beijing 59
Hong Kong 57
Hanoi 46
Ashburn 40
Mexico City 35
Tianjin 30
São Paulo 14
New York 13
Biên Hòa 12
Haiphong 11
Baghdad 10
Da Nang 10
Jakarta 10
Quito 8
Agawam 6
Amman 6
Guangzhou 6
Los Angeles 6
Belo Horizonte 5
Montevideo 5
Rio de Janeiro 5
Can Tho 4
Hải Dương 4
Nha Trang 4
Ninh Bình 4
Oeiras 4
Quảng Ngãi 4
San Jose 4
San Miguel de Tucumán 4
Santiago 4
Thái Bình 4
Al Mansurah 3
Baku 3
Belém 3
Brasília 3
Bucharest 3
Buenos Aires 3
Cairo 3
Campinas 3
Dallas 3
Lima 3
Long An 3
Lấp Vò 3
Medford 3
Orangeburg 3
Porto Alegre 3
Posadas 3
Ribeirão Preto 3
Shanghai 3
Tokyo 3
Turin 3
Vadodara 3
Vienna 3
Alexandria 2
Araraquara 2
Arequipa 2
Asunción 2
Caracas 2
Casablanca 2
Chicago 2
Council Bluffs 2
El Talar 2
Erbil 2
Florianópolis 2
Frankfurt am Main 2
Guadalajara 2
Guarulhos 2
Guayaquil 2
Helsinki 2
Hưng Yên 2
Ismailia 2
Joinville 2
José C. Paz 2
Karachi 2
Kuala Lumpur 2
Langfang 2
Little Rock 2
Lomas de Zamora 2
Manchester 2
Maracaibo 2
Milan 2
Nairobi 2
Niamey 2
Novo Hamburgo 2
Orem 2
Osh 2
Panama City 2
Pasto 2
Paulínia 2
Payne 2
Quilmes Oeste 2
San Juan 2
Santiago del Estero 2
Totale 60.051
Salva come PNG Salva come JPEG
Nome #
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy 281
Immunoterapia specifica: una possibilità di gestione del rischio professionale da allergia al veleno di imenotteri 225
Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early and late phase reactions after allergen-specific challenge. 193
A Review of the Evidence from Comparative Studies of Levocetirizine and Desloratadine for the Symptoms of Allergic Rhinitis 191
Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. 191
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma 185
Adhesion molecules in allergy. 184
NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. 182
A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. 182
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? 177
A double-blind, placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects. 174
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma 174
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience 171
Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. 166
A survey of clinical features of allergic rhinitis in adults. 166
Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. 166
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life 164
Functionally relevant decreases in activatory receptor expression on NK cells are associated with pulmonary tuberculosis in vivo and persist after successful treatment. 162
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19 162
A new protocol for specific oral tolerance induction in children with IgE-mediated cow's milk allergy. 161
The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. 159
Fibrous invasive (Riedel's) thyroiditis with critical response to steroid treatment. 157
Personalized medicine in allergy 157
Local Side Effects of Sublingual and Oral Immunotherapy 156
Nasal cytology: Methodology with application to clinical practice and research 156
Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. 155
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. 155
Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. 155
Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. 154
Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma 154
Current insights in allergen immunotherapy 154
Basi Patogenetiche ed anatomopatologiche della flogosi allergica nell’asma bronchiale 152
Aerobiologic diagnosis of brassicaceae-induced asthma. 152
Catching allergy by a simple questionnaire 152
A critical appraisal on AIT in childhood asthma 152
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma 152
Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. 150
CD4(+)IL-13(+) cells in peripheral blood well correlates with the severity of atopic dermatitis in children. 150
Allergy and the bone: unexpected relationships. 149
A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020 149
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision 148
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation 148
Efficacy of Buffered Hypertonic Saline Nasal Irrigation for Nasal Symptoms in Children with Seasonal Allergic Rhinitis: A Randomized Controlled Trial 148
Umeclidinium for the treatment of uncontrolled asthma 146
Latex-jujube cross-reactivity: case report and immunological study. 145
A prospective italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. 145
Focus on cat allergen (Fel d 1): immunological and aerodynamic characteristics, modality of airway sensitization and avoidance strategies. 145
Continuous versus on demand treatment with cetirizine for allergic rhinitis. 144
Serum cytotoxic T lymphocyte-associated antigen 4 in hymenoptera venom allergy and its modulation by specific immunotherapy 144
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis 143
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy 143
When allergic rhinitis is not only allergic. 143
How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. 142
Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. 141
Allergen-specific nasal challenge: response kinetics of clinical and inflammatory events to rechallenge. 141
The role of basophil activation test in special populations with mastocytosis and reactions to hymenoptera sting. 141
Molecular diagnosis and precision medicine in allergy management 141
Appropriateness in allergic respiratory diseases health care in Italy: Definitions and organizational aspects 141
100 years of immunotherapy: the Monaco charter. under the high patronage of His Serene Highness Prince Albert II of Monaco. 141
An update on the asthma-rhinitis link. 140
The natural history of respiratory allergy: a follow-up study of 99 patients up to 10 years 140
Antihistamines in atopic dermatitis. 140
Sublingual immunotherapy: other indications. 139
Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN) 139
Long-term follow-up of nasal immunotherapy to Parietaria: clinical and local immunological effects. 138
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper 138
Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study. 138
Sublingual and oral immunotherapy. 138
The functional connection between oral allergy syndrome and united airways disease assessed by oral challenge. 138
Sublingual immunotherapy. 138
The safety of monoclonal antibodies in asthma 138
The classification of allergic rhinitis and its cytological correlate. 138
The path to personalized medicine in asthma 138
Allergenius, an expert system for the interpretation of allergen microarray results 138
Evidence of desloratadine syrup efficacy and tolerability in children with pollen-induced allergic rhinitis. 137
The asthma-rhinitis association: between the clinical hypothesis and the scientific theory. 136
Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. 136
Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study 136
New insights in sublingual immunotherapy. 135
Prevalence of allergy to Cypress. 135
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations 135
[Anti-leukotriene agents: rationale for and prospects of use]. 135
AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation 135
A WAO-ARIA-GA2LEN consensus document on molecular-based allergy diagnostics 135
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. 135
United airways disease: therapeutic aspects 134
Safety of sublingual immunotherapy with a monomeric allergoid in very young children. 134
Exercise-induced anaphylaxis to grape. 134
Efficacy of sublingual immunotherapy. 134
Executive summary of European Task Force document on diagnostic tools in rhinology. 134
Will sublingual immunotherapy offer benefit for asthma? 134
Hymenoptera venom allergy in outdoor workers: Occupational exposure, clinical features and effects of allergen immunotherapy 134
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 134
Adherence to sublingual immunotherapy in preschool children. 134
Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation 134
Antihistamines in the treatment of bronchial asthma. Present knowledge and future perspectives 133
New perspectives in the treatment of allergic rhinitis and asthma in children 133
Continuous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy. 133
Allergic rhinitis and its impact on asthma update: allergen immunotherapy. 133
Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. 133
Totale 15.030
Salva come PNG Salva come JPEG
Categoria #
all - tutte 198.691
article - articoli 197.637
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.054
Totale 397.382
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.515 0 0 0 0 0 323 216 419 358 470 273 456
2021/20226.596 152 387 560 940 117 560 551 1.378 276 571 310 794
2022/20235.473 598 221 30 477 836 1.112 52 508 1.078 96 388 77
2023/20242.361 177 419 52 195 233 362 122 106 129 47 162 357
2024/20256.939 101 700 275 440 1.060 682 659 861 267 382 575 937
2025/20265.215 1.237 385 854 945 1.457 337 0 0 0 0 0 0
Totale 61.692